Developer docs
API playgroundTry for free, no card

Search company profiles

CivicaScript

Full company profile

uuid00kd9zh

Namestring
CivicaScript
Legal namestring
CivicaScript, LLC
Company typeenum
Private
Founded yearint
2020
Descriptiontext

CivicaScript is a nonprofit pharmaceutical company, organized as an LLC and operating as the outpatient-medicines unit of parent nonprofit Civica, Inc. Founded in 2020 and headquartered in Lehi, Utah, with a manufacturing/operations facility in Petersburg, Virginia, the company develops, manufactures, and distributes low-cost generic medicines and biosimilars targeting high-priced outpatient drugs where generic pricing has failed patients. Its portfolio spans specialty generics (abiraterone/Abirtega for prostate cancer, capecitabine for colorectal/breast/gastric/esophageal/pancreatic cancer, dalfampridine for multiple sclerosis, dimethyl fumarate for chronic inflammatory conditions, droxidopa for orthostatic hypotension) and biosimilars (insulin glargine-yfgn interchangeable with Lantus, and ustekinumab-aauz for immunology indications). Products are sourced through manufacturer partnerships including Biocon Biologics (insulin) and Fresenius Kabi (ustekinumab).

The company sells products to pharmacies at wholesale prices with a publicly disclosed Maximum Retail Price (MaxRP) cap enforced via its Unilateral Pricing Policy and QR-code-enabled package verification, eliminating conventional markup opacity. CivicaScript is funded and governed by its members: 18 founding independent Blue Cross and Blue Shield plans, the Blue Cross Blue Shield Association, Elevance Health/CarelonRx (covering more than 47 million lives), and PBMs including Navitus Health Solutions, Affirmed Rx, and SelectHealth/Scripius. Distribution flows through these payer and PBM channels to pharmacies and, in California, through the state CalRx program for insulin. Per NEJM Catalyst (Vol. 6 No. 6, June 2025), switching to CivicaScript abiraterone yielded 64% cost savings for patients and 92% for payers; the company reported $16 million in savings delivered in 2025 and nearly $44 million cumulatively since its 2022 product launch.

Short descriptiontext

CivicaScript is a nonprofit pharmaceutical company, founded in 2020 as a subsidiary of Civica, Inc., that develops and distributes low-cost generic medicines and biosimilars to U.S. payers, PBMs, and pharmacies through its MaxRP transparent pricing model. It is governed by Blue Cross Blue Shield plans, Elevance Health, and PBM members covering tens of millions of lives.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLehi, United States
HQ citystring
Lehi
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic medicines, biosimilar pharmaceuticals, drug pricing transparency, nonprofit pharmaceutical, specialty generic drugs
Industry1 code
PRIMARYHLAFALAL
340B Program Administration & Contract Pharmacy Services
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
NAICS code1 code
  • Civic and Social Organizations81341
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Generic Medicine Sales
TypeOne Time License
Description

CivicaScript manufactures low-cost generic medicines and works with payers, PBMs and pharmacies across the country to pass along cost savings to patients. As a nonprofit, revenue is reinvested to support the mission of providing affordable essential generic medicines.

civicascript.com
2Biosimilar Distribution
TypeOne Time License
Description

CivicaScript distributes biosimilars including insulin glargine-yfgn and ustekinumab-aauz. Products are sold to pharmacies at wholesale prices with maximum recommended retail prices to consumers.

civicascript.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Pricing details12 tiers
1Abirtega (abiraterone), 250 mg: 120 tablets - $141
ModelUnit PricingBilling cadencePay-as-you-go
Notes

MaxRP price to consumer: $141 per 120-tablet bottle. CivicaScript's abiraterone had a MaxRP of $171 per month.

civicascript.com
2Capecitabine, 150 mg: 60 tablets - $38
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Capecitabine 150 mg film-coated tablets at $38 per 60-tablet bottle. Potential savings of $1,500/month compared to other generic versions.

civicascript.com
3Capecitabine, 500 mg: 120 tablets - $84
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Capecitabine 500 mg film-coated tablets at $84 per 120-tablet bottle. Pharmacy cost: $63 per bottle.

civicascript.com
4Civica insulin glargine-ygfn, box of 5 prefilled pens - $55
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Sold to pharmacies for $45 for a box of five pens. MaxRP for consumers is no more than $55. Available nationwide; CalRx brand in California.

civicascript.com
5Dalfampridine, 10 mg: 60 extended-release tablets - $37
ModelUnit PricingBilling cadencePay-as-you-go
Notes

One-month supply at $37 per bottle. Potential savings of $960/month compared to other generic versions.

civicascript.com
6Dimethyl fumarate, 120 mg: 14 capsules - $46
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Dimethyl fumarate delayed-release capsules, 120 mg, 14 capsules at $46.

civicascript.com
7Dimethyl fumarate, 240 mg: 60 capsules - $68
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Dimethyl fumarate delayed-release capsules, 240 mg, 60 capsules at $68.

civicascript.com
8Droxidopa, 100 mg: 90 capsules - $65
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Droxidopa capsules, 100 mg, 90 capsules at $65.

civicascript.com
9Droxidopa, 200 mg: 90 capsules - $109
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Droxidopa capsules, 200 mg, 90 capsules at $109.

civicascript.com
10Droxidopa, 300 mg: 90 capsules - $153
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Droxidopa capsules, 300 mg, 90 capsules at $153.

civicascript.com
11Ustekinumab-aauz, 45 mg - $625
ModelUnit PricingBilling cadencePay-as-you-go
Notes

WAC for 12-week supply of 45 mg is $575.

civicascript.com
12Ustekinumab-aauz, 90 mg - $1,035
ModelUnit PricingBilling cadencePay-as-you-go
Notes

WAC for 12-week supply of 90 mg is $985.

civicascript.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Abirtega
Description

Proprietary brand name for abiraterone 250 mg tablets

civicascript.com
+2 more records
Core offering1 text field

CivicaScript is a nonprofit pharmaceutical company that manufactures and distributes low-cost essential generic medicines and biosimilars through partnerships with payers, pharmacy benefit managers (PBMs), and pharmacies. The company employs a Maximum Retail Price (MaxRP) pricing policy with QR-code-based verification to ensure price transparency throughout the supply chain, passing savings to patients and health plan members.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Patients who switched to CivicaScript abiraterone saved about $81 per month on average (64 percent)
+7 more records
Product overview1 text field

CivicaScript is a nonprofit pharmaceutical company operating as the Civica, Inc. operating unit for outpatient medications, focused on making essential generic medicines and biosimilars affordable and available to everyone. The company manufactures and distributes low-cost generic medicines through partnerships with payers, pharmacy benefit managers (PBMs), and pharmacies. The portfolio includes specialty generics (Abirtega/abiraterone, capecitabine, dalfampridine, dimethyl fumarate, droxidopa) and biosimilars (insulin glargine-yfgn, ustekinumab-aauz). All products feature the MaxRP pricing policy enabling price transparency through QR codes. The business model emphasizes transparency and collaboration throughout the supply chain from manufacturing through dispensing.

Product and service7 records
1Abirtega (abiraterone acetate)
CategoryGeneric medication
Description

Generic abiraterone 250 mg tablets (120 per bottle, MaxRP $141), used for prostate cancer treatment. CivicaScript's first product, launched in August 2022.

2Capecitabine
CategoryGeneric medication
Description

Generic capecitabine film-coated tablets for colorectal, breast, gastric, esophageal, gastroesophageal junction, or pancreatic cancer. Available in 150 mg (60 tablets, $38) and 500 mg (120 tablets, $84).

3Dalfampridine
CategoryGeneric medication
Description

Generic dalfampridine 10 mg extended-release tablets (60 tablets, $37/month supply), a potassium channel blocker indicated to improve walking in adults with multiple sclerosis.

4Dimethyl fumarate
CategoryGeneric medication
Description

Generic dimethyl fumarate delayed-release capsules for chronic inflammatory conditions. Available in 120 mg (14 capsules, $46) and 240 mg (60 capsules, $68).

5Droxidopa
CategoryGeneric medication
Description

Generic droxidopa capsules for orthostatic hypotension. Available in 100 mg (90 capsules, $65), 200 mg (90 capsules, $109), and 300 mg (90 capsules, $153).

6Insulin glargine-yfgn
CategoryBiosimilar insulin
Description

Long-acting insulin glargine in prefilled pens (box of 5 pens, $55 MaxRP). Interchangeable with Lantus. Manufactured by Biocon Biologics. Available nationally; sold under CalRx brand in California.

7Ustekinumab-aauz
CategoryBiosimilar
Description

Biosimilar ustekinumab (interchangeable with Stelara) for chronic inflammatory conditions. Human monoclonal antibody targeting IL-12 and IL-23 cytokines. Available in 45 mg ($625) and 90 mg ($1,035) prefilled syringes.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Biocon Biologics manufactures insulin glargine-yfgn under its existing U.S. marketing approval. Partnership brings affordable biosimilar insulin to market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

Fresenius Kabi produces ustekinumab-aauz biosimilar. CivicaScript is the exclusive distributor of unbranded ustekinumab-aauz.

3California CalRx Program
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnership with California Department of Health Care Access and Information. Insulin glargine-yfgn carries the CalRx brand in California pharmacies.

civicascript.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Breakthrough T1D (formerly JDRF) has joined with more than 25 other philanthropic partners and the states of California and Virginia to support Civica's development of three commonly prescribed insulin types.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Nonprofit PBM (formerly SelectHealth) joined as a new partnering member in 2023.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Navitus Health Solutions is a PBM founding member. Brent Eberle joined CivicaScript in 2024 after two decades of leadership at Navitus.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Affirmed Rx was the first pharmacy benefit manager to join as a partnering member in 2022.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Elevance Health (formerly Anthem) operates affiliated health plans covering more than 47 million people in the U.S. and joined as a founding member.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

CivicaScript was created by Civica (the parent nonprofit) and Blue Cross Blue Shield organizations. Civica provides operational infrastructure and manufacturing partnerships. Functional operations for CivicaScript are integrated with Civica.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

BCBSA co-founded CivicaScript with Civica to bring affordable versions of commonly prescribed but high-priced generic medicines to market. The association continues to champion the model with Blue Plans nationwide.

1118 Independent Blue Cross and Blue Shield Companies
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

18 independent and locally operated Blue Cross and Blue Shield companies co-founded CivicaScript as founding members.

civicascript.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Public-benefit pharmaceutical manufacturer focused on domestic production of essential medicines and APIs; similarly mission-driven with government/Civica-style backing, making it a natural peer in the nonprofit essential-medicines manufacturing space.

2Sandoz (Novartis division)
TypeBroad incumbent
Description

World's largest generic and biosimilar manufacturer with thousands of SKUs across retail and specialty — comparable as a broad incumbent in low-cost generics, though pursuing a for-profit model with opposite incentives.

TypeBroad incumbent
Description

Parent nonprofit organization focused on hospital-administered generic drug shortages and price gouging; CivicaScript was created as Civica's outpatient/retail extension and shares operational infrastructure, manufacturing partnerships and the nonprofit mission.

TypeDirect peer
Description

Commercial biosimilar developer (ranibizumab, pegfilgrastim, adalimumab, ustekinumab) competing in the same therapeutic categories where CivicaScript is launching biosimilars, with similar cost-positioning strategy versus originator biologics.

TypeDirect peer
Description

Online pharmacy selling generics at cost-plus transparent markup with public price lists — the most direct peer in business model (transparent, mission-driven generic distribution) and target customer overlap (price-sensitive payers and uninsured patients).

TypeDirect peer
Description

Pure-play biosimilar developer with interchangeable biosimilars (insulin, ustekinumab, denosumab, aflibercept) directly overlapping CivicaScript's biosimilar pipeline and interchangeable-insulin positioning with Biocon.

7GoodRx
TypeOthers
Description

Public prescription price-transparency and discount platform; not a manufacturer but a peer in the consumer-facing drug-pricing-transparency thesis and partner/customer overlap with cost-sensitive patients and payers.

TypeBroad incumbent
Description

World's largest generic manufacturer by volume with broad retail-generic presence; competes in essentially every category CivicaScript targets, though as a for-profit incumbent without pricing-transparency mechanisms.

TypeBroad incumbent
Description

Specialty generics and injectables manufacturer with strong U.S. retail presence; comparable as a mid-size specialty-generic incumbent pursuing many of the same therapeutic indications (oncology, MS, etc.) as CivicaScript.

TypeBroad incumbent
Description

Global generics + biosimilars + specialty player with a deep specialty-generic portfolio (including authorized generics) overlapping CivicaScript's therapeutic categories and competing for the same payer formulary slots.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers26 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CivicaScript

Generic Pharmaceuticalscivicascript.com

CivicaScript is a nonprofit pharmaceutical company, founded in 2020 as a subsidiary of Civica, Inc., that develops and distributes low-cost generic medicines and biosimilars to U.S. payers, PBMs, and pharmacies through its MaxRP transparent pricing model. It is governed by Blue Cross Blue Shield plans, Elevance Health, and PBM members covering tens of millions of lives.

What CivicaScript does

CivicaScript is a nonprofit pharmaceutical company, organized as an LLC and operating as the outpatient-medicines unit of parent nonprofit Civica, Inc. Founded in 2020 and headquartered in Lehi, Utah, with a manufacturing/operations facility in Petersburg, Virginia, the company develops, manufactures, and distributes low-cost generic medicines and biosimilars targeting high-priced outpatient drugs where generic pricing has failed patients. Its portfolio spans specialty generics (abiraterone/Abirtega for prostate cancer, capecitabine for colorectal/breast/gastric/esophageal/pancreatic cancer, dalfampridine for multiple sclerosis, dimethyl fumarate for chronic inflammatory conditions, droxidopa for orthostatic hypotension) and biosimilars (insulin glargine-yfgn interchangeable with Lantus, and ustekinumab-aauz for immunology indications). Products are sourced through manufacturer partnerships including Biocon Biologics (insulin) and Fresenius Kabi (ustekinumab).

The company sells products to pharmacies at wholesale prices with a publicly disclosed Maximum Retail Price (MaxRP) cap enforced via its Unilateral Pricing Policy and QR-code-enabled package verification, eliminating conventional markup opacity. CivicaScript is funded and governed by its members: 18 founding independent Blue Cross and Blue Shield plans, the Blue Cross Blue Shield Association, Elevance Health/CarelonRx (covering more than 47 million lives), and PBMs including Navitus Health Solutions, Affirmed Rx, and SelectHealth/Scripius. Distribution flows through these payer and PBM channels to pharmacies and, in California, through the state CalRx program for insulin. Per NEJM Catalyst (Vol. 6 No. 6, June 2025), switching to CivicaScript abiraterone yielded 64% cost savings for patients and 92% for payers; the company reported $16 million in savings delivered in 2025 and nearly $44 million cumulatively since its 2022 product launch.

CivicaScript firmographics

Firmographics
Name
CivicaScript
Legal name
CivicaScript, LLC
Website
https://civicascript.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
CivicaScript is a nonprofit pharmaceutical company, founded in 2020 as a subsidiary of Civica, Inc., that develops and distributes low-cost generic medicines and biosimilars to U.S. payers, PBMs, and pharmacies through its MaxRP transparent pricing model. It is governed by Blue Cross Blue Shield plans, Elevance Health, and PBM members covering tens of millions of lives.
Ownership category
akta.pro rank

CivicaScript industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Civic and Social Organizations (81341)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAFALAL
340B Program Administration & Contract Pharmacy Services
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services

Keywords

  • Generic medicines
  • Biosimilar pharmaceuticals
  • Drug pricing transparency
  • Nonprofit pharmaceutical
  • Specialty generic drugs

Where CivicaScript is headquartered

Location

Headquarters

HQ city
Lehi
HQ country
United States
HQ region
North America

Offices2 records

Markets served

CivicaScript business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Generic Medicine Sales: CivicaScript manufactures low-cost generic medicines and works with payers, PBMs and pharmacies across the country to pass along cost savings to patients. As a nonprofit, revenue is reinvested to support the mission of providing affordable essential generic medicines.
  2. Biosimilar Distribution: CivicaScript distributes biosimilars including insulin glargine-yfgn and ustekinumab-aauz. Products are sold to pharmacies at wholesale prices with maximum recommended retail prices to consumers.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAbirtega (abiraterone), 250 mg: 120 tablets - $141
Unit PricingPay-as-you-goCapecitabine, 150 mg: 60 tablets - $38
Unit PricingPay-as-you-goCapecitabine, 500 mg: 120 tablets - $84
Unit PricingPay-as-you-goCivica insulin glargine-ygfn, box of 5 prefilled pens - $55
Unit PricingPay-as-you-goDalfampridine, 10 mg: 60 extended-release tablets - $37
Unit PricingPay-as-you-goDimethyl fumarate, 120 mg: 14 capsules - $46
Unit PricingPay-as-you-goDimethyl fumarate, 240 mg: 60 capsules - $68
Unit PricingPay-as-you-goDroxidopa, 100 mg: 90 capsules - $65
Unit PricingPay-as-you-goDroxidopa, 200 mg: 90 capsules - $109
Unit PricingPay-as-you-goDroxidopa, 300 mg: 90 capsules - $153
Unit PricingPay-as-you-goUstekinumab-aauz, 45 mg - $625
Unit PricingPay-as-you-goUstekinumab-aauz, 90 mg - $1,035

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

CivicaScript product offering

Product offering

Core offering

CivicaScript is a nonprofit pharmaceutical company that manufactures and distributes low-cost essential generic medicines and biosimilars through partnerships with payers, pharmacy benefit managers (PBMs), and pharmacies. The company employs a Maximum Retail Price (MaxRP) pricing policy with QR-code-based verification to ensure price transparency throughout the supply chain, passing savings to patients and health plan members.

Product overview

CivicaScript is a nonprofit pharmaceutical company operating as the Civica, Inc. operating unit for outpatient medications, focused on making essential generic medicines and biosimilars affordable and available to everyone. The company manufactures and distributes low-cost generic medicines through partnerships with payers, pharmacy benefit managers (PBMs), and pharmacies. The portfolio includes specialty generics (Abirtega/abiraterone, capecitabine, dalfampridine, dimethyl fumarate, droxidopa) and biosimilars (insulin glargine-yfgn, ustekinumab-aauz). All products feature the MaxRP pricing policy enabling price transparency through QR codes. The business model emphasizes transparency and collaboration throughout the supply chain from manufacturing through dispensing.

Differentiator

Problem solved

Functional benefit

Brands

  • Abirtega: Proprietary brand name for abiraterone 250 mg tablets
  • CalRx
  • MaxRP

Products and services

  • Abirtega (abiraterone acetate) Generic abiraterone 250 mg tablets (120 per bottle, MaxRP $141), used for prostate cancer treatment. CivicaScript's first product, launched in August 2022.
  • Capecitabine Generic capecitabine film-coated tablets for colorectal, breast, gastric, esophageal, gastroesophageal junction, or pancreatic cancer. Available in 150 mg (60 tablets, $38) and 500 mg (120 tablets, $84).
  • Dalfampridine Generic dalfampridine 10 mg extended-release tablets (60 tablets, $37/month supply), a potassium channel blocker indicated to improve walking in adults with multiple sclerosis.
  • Dimethyl fumarate Generic dimethyl fumarate delayed-release capsules for chronic inflammatory conditions. Available in 120 mg (14 capsules, $46) and 240 mg (60 capsules, $68).
  • Droxidopa Generic droxidopa capsules for orthostatic hypotension. Available in 100 mg (90 capsules, $65), 200 mg (90 capsules, $109), and 300 mg (90 capsules, $153).
  • Insulin glargine-yfgn Long-acting insulin glargine in prefilled pens (box of 5 pens, $55 MaxRP). Interchangeable with Lantus. Manufactured by Biocon Biologics. Available nationally; sold under CalRx brand in California.
  • Ustekinumab-aauz Biosimilar ustekinumab (interchangeable with Stelara) for chronic inflammatory conditions. Human monoclonal antibody targeting IL-12 and IL-23 cytokines. Available in 45 mg ($625) and 90 mg ($1,035) prefilled syringes.

Quantifiable outcome

  • Patients who switched to CivicaScript abiraterone saved about $81 per month on average (64 percent)
  • +7 more outcomes

Companies that use CivicaScript

Customer profile

Named customers26 records

Segments3 records

Ideal customer profiles2 records

CivicaScript technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

CivicaScript partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and major.

  • Biocon BiologicscoreStrategic or Co-development Partner · 1 October 2025Biocon Biologics manufactures insulin glargine-yfgn under its existing U.S. marketing approval. Partnership brings affordable biosimilar insulin to market.
  • Fresenius KabicoreStrategic or Co-development Partner · 1 August 2025Fresenius Kabi produces ustekinumab-aauz biosimilar. CivicaScript is the exclusive distributor of unbranded ustekinumab-aauz.
  • California CalRx ProgramcoreStrategic or Co-development Partner · 1 January 2025Partnership with California Department of Health Care Access and Information. Insulin glargine-yfgn carries the CalRx brand in California pharmacies.
  • Breakthrough T1DmajorStrategic or Co-development Partner · 1 January 2025Breakthrough T1D (formerly JDRF) has joined with more than 25 other philanthropic partners and the states of California and Virginia to support Civica's development of three commonly prescribed insulin types.
  • SelectHealth/ScripiusmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Nonprofit PBM (formerly SelectHealth) joined as a new partnering member in 2023.
  • Navitus Health SolutionscoreChannel Partner/ Reseller/ Distributor · 1 January 2022Navitus Health Solutions is a PBM founding member. Brent Eberle joined CivicaScript in 2024 after two decades of leadership at Navitus.
  • Affirmed RxcoreChannel Partner/ Reseller/ Distributor · 1 January 2022Affirmed Rx was the first pharmacy benefit manager to join as a partnering member in 2022.
  • Elevance Health / CarelonRxcoreChannel Partner/ Reseller/ Distributor · 1 January 2021Elevance Health (formerly Anthem) operates affiliated health plans covering more than 47 million people in the U.S. and joined as a founding member.
  • CivicacoreStrategic or Co-development Partner · 1 January 2020CivicaScript was created by Civica (the parent nonprofit) and Blue Cross Blue Shield organizations. Civica provides operational infrastructure and manufacturing partnerships. Functional operations for CivicaScript are integrated with Civica.
  • Blue Cross Blue Shield AssociationcoreStrategic or Co-development Partner · 1 January 2020BCBSA co-founded CivicaScript with Civica to bring affordable versions of commonly prescribed but high-priced generic medicines to market. The association continues to champion the model with Blue Plans nationwide.
  • 18 Independent Blue Cross and Blue Shield CompaniescoreStrategic or Co-development Partner · 1 January 202018 independent and locally operated Blue Cross and Blue Shield companies co-founded CivicaScript as founding members.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

CivicaScript competitors and assessment

Company assessment

Emerging players

  • Phlow Corporation: Public-benefit pharmaceutical manufacturer focused on domestic production of essential medicines and APIs; similarly mission-driven with government/Civica-style backing, making it a natural peer in the nonprofit essential-medicines manufacturing space.

Broad incumbents

  • Sandoz (Novartis division): World's largest generic and biosimilar manufacturer with thousands of SKUs across retail and specialty — comparable as a broad incumbent in low-cost generics, though pursuing a for-profit model with opposite incentives.
  • Civica (Civica, Inc.): Parent nonprofit organization focused on hospital-administered generic drug shortages and price gouging; CivicaScript was created as Civica's outpatient/retail extension and shares operational infrastructure, manufacturing partnerships and the nonprofit mission.
  • Teva Pharmaceutical Industries: World's largest generic manufacturer by volume with broad retail-generic presence; competes in essentially every category CivicaScript targets, though as a for-profit incumbent without pricing-transparency mechanisms.
  • Hikma Pharmaceuticals: Specialty generics and injectables manufacturer with strong U.S. retail presence; comparable as a mid-size specialty-generic incumbent pursuing many of the same therapeutic indications (oncology, MS, etc.) as CivicaScript.
  • Viatris: Global generics + biosimilars + specialty player with a deep specialty-generic portfolio (including authorized generics) overlapping CivicaScript's therapeutic categories and competing for the same payer formulary slots.

Direct peers

  • Coherus BioSciences: Commercial biosimilar developer (ranibizumab, pegfilgrastim, adalimumab, ustekinumab) competing in the same therapeutic categories where CivicaScript is launching biosimilars, with similar cost-positioning strategy versus originator biologics.
  • Mark Cuban Cost Plus Drug Company: Online pharmacy selling generics at cost-plus transparent markup with public price lists — the most direct peer in business model (transparent, mission-driven generic distribution) and target customer overlap (price-sensitive payers and uninsured patients).
  • Alvotech: Pure-play biosimilar developer with interchangeable biosimilars (insulin, ustekinumab, denosumab, aflibercept) directly overlapping CivicaScript's biosimilar pipeline and interchangeable-insulin positioning with Biocon.

Others

  • GoodRx: Public prescription price-transparency and discount platform; not a manufacturer but a peer in the consumer-facing drug-pricing-transparency thesis and partner/customer overlap with cost-sensitive patients and payers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CivicaScript social profiles

Digital presence

CivicaScript financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CivicaScript leadership team

Management profile

Number of profiles

Profiles10 records

CivicaScript funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CivicaScript M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CivicaScript

What does CivicaScript do?

CivicaScript is a nonprofit pharmaceutical company that manufactures and distributes low-cost essential generic medicines and biosimilars through partnerships with payers, pharmacy benefit managers (PBMs), and pharmacies. The company employs a Maximum Retail Price (MaxRP) pricing policy with QR-code-based verification to ensure price transparency throughout the supply chain, passing savings to patients and health plan members.

Is CivicaScript a public or private company?

CivicaScript is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was CivicaScript founded?

CivicaScript was founded in 2020. It employs 1 to 10 people.

Where is CivicaScript based?

CivicaScript is headquartered in Lehi, United States, in the North America region.

How does CivicaScript make money?

Two revenue lines are on record. Generic Medicine Sales are the primary driver. The others are biosimilar Distribution.

Who are CivicaScript's main competitors?

Phlow Corporation is listed as an emerging player. Broad incumbents are Sandoz (Novartis division), Civica (Civica, Inc.), Teva Pharmaceutical Industries, Hikma Pharmaceuticals and Viatris. Direct peers are Coherus BioSciences, Mark Cuban Cost Plus Drug Company and Alvotech. GoodRx is listed as an others.

Does CivicaScript have an API?

No public API is recorded for CivicaScript.

What industry is CivicaScript in?

CivicaScript's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAFALAL, 340B Program Administration & Contract Pharmacy Services. Its NAICS code is 81341 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCivicaScript® launches 3 low-cost generics to expand its market impactCivicaScript announced three new low-cost generic products: Yulithira (everolimus), fingolimod, and imatinib mesylate, available nationwide. The products' recommended prices are up to 98% lower than average generic versions, with savings of $1,631, $1,032, and $5,564 per month respectively. The company has delivered nearly $44 million in savings since 2022.PR NewswireCivicaScript® to distribute low-cost biosimilar to treat chronic inflammatory conditionsCivicaScript announced it will distribute the biosimilar ustekinumab-aauz, a treatment for chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, starting January 1, 2026. The product, manufactured by Fresenius Kabi, will be sold at a wholesale acquisition price of $575 for 45mg and $985 for 90mg per 12-week supply, representing a significant discount to the branded reference product Stelara. The launch expands CivicaScript's specialty generic portfolio and marks its entry into the biosimilars market as it works to reduce healthcare costs for U.S. patients.PR NewswireCivicaScript® Launches Low-Cost Multiple Sclerosis Treatment to Increase Patient Access, Create Significant SavingsCivicaScript announced the launch of low-cost dimethyl fumarate delayed-release capsules for treating relapsing forms of multiple sclerosis in adults. The generic medication will be sold to pharmacies for $47 per bottle of 60 capsules with a recommended maximum retail price of $68, offering approximately $4,300 in monthly savings compared to average claim costs at traditional PBM-affiliated pharmacies. This marks the company's second generic drug launch in three months, continuing its nonprofit mission to bring transparency and affordability to the US generic drug market.PR NewswireNew report shows CivicaScript's novel business model saves money for consumers, payersA NEJM Catalyst analysis found CivicaScript's abiraterone saves patients 64% and payers 92% compared to competing generics. The nonprofit's disruptive collaboration model passed savings through the supply chain, with about 1,100 patients using the drug by December 2023. CivicaScript expects additional products to launch this year.AnthembluecrossSpecialty Pharmacy Benefits & Total Cost of CareThe article advocates for integrating specialty pharmacy benefits into medical plans to help employers manage the rising costs of high-priced drugs and gene therapies. It highlights initiatives by Blue Cross Blue Shield, including CivicaScript and Synergie Medication Collective, aimed at improving affordability through coordinated care and value-based contracting. The report suggests that such integration can lead to significant savings in total cost of care and improved patient outcomes.GlobeNewswireSocietal CDMO Signs Master Service Agreement With CivicaScript to Provide CDMO ServicesSocietal CDMO signed a master service agreement with CivicaScript to provide CDMO services for a generic drug candidate. The agreement covers formulation, process development, and registration-scale batch manufacturing for clinical trial materials. The work may expand to include additional CivicaScript programs.GlobeNewswireSocietal CDMO Signs Master Service Agreement With CivicaScript to Provide CDMO ServicesSocietal CDMO signed a master service agreement with CivicaScript to provide CDMO services for a generic drug candidate. The agreement covers formulation, process development, and registration-scale batch manufacturing for clinical trial materials. The work may expand to include additional CivicaScript programs.AxiosHow companies are shaking up how we pay for old drugsCivicaScript, a hospital-owned nonprofit, will sell a generic version of abiraterone for about $160 per month, roughly $3,000 less than the average price for Medicare Part D coverage. The company says this is its first drug and aims to increase transparency in generics pricing.FierceHealthcareNavitus Health Solutions signs on with CivicaScript to address high-cost genericsNavitus Health Solutions joined CivicaScript as a founding member, aiming to distribute low-cost generic drugs to its 8.7 million members. CivicaScript will initially focus on six to ten medicines, with the first launch expected later this summer.GlobeNewswireEmsanaRx Joins CivicaScript to Make Lower-Cost Generic Medicines Available to its Pharmacy Benefit MembersEmsanaRx, a pharmacy benefit manager for self-funded employers, joined CivicaScript to make lower-cost generic medicines available to its members. The partnership aims to address high generic drug costs, with CivicaScript's first medication expected late this summer. EmsanaRx spends over $140 billion annually on prescription drugs for its members.